Evaluation of the Response to Monoclonal Antibody Therapy in Severe Asthma: Research of Predictive Biomarkers in Exhaled Air
NCT ID: NCT03988790
Last Updated: 2021-02-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
50 participants
INTERVENTIONAL
2018-12-04
2022-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of Volatile Organic Compounds in Mepolizumab Therapy
NCT04924478
Anti-IgE Monoclonal Antibody Treatment in Patients With Allergic Asthma.
NCT03468790
Severe Asthma Exacerbations and Mepolizumab Treatment
NCT04914078
A Study of CM310 in Subjects With Moderate to Severe Asthma
NCT05186909
Cohort Analysis of Clinical and Biological Severe Childhood Asthma
NCT02114034
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The evaluation of the answer, and even better the answer prediction, are fundamental issues for medico-economic plan as part of these innovative therapeutics.
The interest of the use of VOC as diagnostic or prognostic tool in patients with tumoral thoracic pathology or bronchial or pulmonary vascular diseases has been demonstrated.
VOC analysis will be performed using two different techniques: electronic nose and masse spectrometry. At each visit, in addition to the usual assessment, patients will have two non-invasives collections of exhaled air, one for electronic nose analysis and one for masse spectrometry analysis.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
VOC analysis
VOC analysis in exhaled air in patients with severe asthma treated by monoclonal antibody
VOC analysis
VOC analysis in exhaled air with e-noses and mass spectrometry.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
VOC analysis
VOC analysis in exhaled air with e-noses and mass spectrometry.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* patient with severe asthma who respond to the indication of monoclonal antibody therapy according to SPC and management criteria fixed by Transparency Committee
* signed informed consent
* patient with healthcare insurance
Exclusion Criteria
* contraindication to one of monoclonal antibody treatment according to SPC (hypersensitivity to one of compounds)
* patient unable to perform a slow vital capacity
* patient with long-term oxygen therapy , under invasive ventilation
* pregnant women
* patient deprived of liberty by judicial or administrative decision
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hopital Foch
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Philippe Devillier
Role: PRINCIPAL_INVESTIGATOR
Pneumology department
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hôpital Foch
Suresnes, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2018_0075
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.